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INTRODUCTION
Cells, whether normal or malignant, have the ability to
‘sense’ low oxygen condition, probably via a heme flavo-oxido-
reductase protein or even through hypoxia-stimulated release
of reactive oxygen species from mitochondria (1), which acti-
vates a signaling pathway for the expression of the hypoxia-
regulated genes. A widespread oxygen sensing system exists
in mammalian cells. This regulates the expression of a diverse
group of genes including erythropoietin, glucose transporters,
glycolytic pathway enzymes, vascular endothelial growth fac-
tor (VEGF), transferrin, heme oxygenase, and inducible nitric
oxide synthetase, many of which are known to be up-regu-
lated in cancer (2). In tumor cell lines, hypoxia-regulated gene
expression has been shown to involve the stabilization, nucle-
ar accumulation, and DNA binding of the transcription fac-
tors hypoxia inducible factors (HIFs). These proteins are het-
erodimers consisting of two different, hypoxia-inducible alpha
subunits (HIF-1 and HIF-2 ) and a common, constitutive
beta subunits (HIF-1 ) identical to aryl hydrocarbon nuclear
receptor translocator (ARNT) (3, 4). The critical determinant
of HIF activity is the level of HIF-1 or HIF-2 protein,
since ARNT or HIF-1 is constitutively present (5). On expo-
sure to hypoxia, both HIF-1 and HIF-2 proteins accumu-
late rapidly in the nucleus and bind to short DNA sequences
called hypoxia-response elements near or in oxygen-sensitive
genes, stimulating gene expression. Although the exact mech-
anism of oxygen sensing remains to be elucidated, the cell
probably senses its oxygen concentration through reactive
oxygen species, so that stabilization of HIF-1 or HIF-2
protein is said to be redox induced (6). With reoxygenation,
they disappear and their cellular levels are determined main-
ly by the rate of ubiquitin-proteasomal degradation (7).
Regions of hypoxia are known to exist within many tumors,
and the extent of tumor hypoxia correlates with prognosis in
a number of tumor types (8, 9). Hypoxia in the tumor micro-
environment is sufficient to activate HIF-dependent gene ex-
pression (10). A major role of HIF proteins in determining
gene expression, tumor angiogenesis, and growth has been
demonstrated in xenograft experiments with a cell line defi-
cient in ARNT (11). Description of the distribution within
human tissue of HIF-1 has primarily been of mRNA. But
the nuclear accumulation of HIF-1 protein can be also detect-
ed immunohistochemically and has been shown to occur in
human malignancies and their metastases (12). Recently Gia-
tromanolaki et al. (13) reported that the immunohistochemi-
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Differential Expression of Hypoxia Inducible Factor-1 and Tumor Cell
Proliferation Between Squamous Cell Carcinomas and
Adenocarcinomas Among Operable Non-Small Cell Lung Carcinomas 
This study aimed to evaluate whether the elevated level of hypoxia-inducible factor-
1 (HIF-1 ) correlated with histologic types, angiogenesis, tumor cell proliferation,
and clinical parameters in common non-small cell lung carcinomas (NSCLCs). We
performed immunohistochemical stains using paraffin-embedded tissue blocks from
84 cases of operable NSCLC [No. of squamous cell carcinoma (SCC), 45; No. of
adenocarcinoma (AC), 39]. HIF-1 expression was related with histologic types
(66.7% in SCCs vs 20.5% in ACs, p<0.001), but not with lymph node status, tumor
stage, vascular endothelial growth factor expression, microvessel density (MVD),
and proliferating cell nuclear antigen (PCNA) index (p>0.05, respectively). As for the
histologic types, MVD and PCNA index were significantly higher in SCCs than in
ACs (p=0.009 and p=0.016, respectively). Among HIF-1 positive carcinomas, MVD
was significantly higher in HIF-1 positive SCCs than in HIF-1 positive ACs (p=
0.023). The overall survival curves were not associated with HIF-1 expression or
any other histologic parameters (p>0.05). These findings suggest that HIF-1 expres-
sion in NSCLCs may play a differential role according to histologic types, but its prog-
nostic significance is indeterminate.
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cal expression of HIF-1 and HIF-2 proteins in non-small
cell lung carcinomas (NSCLCs) was related to the up-regula-
tion of various angiogenic factors including VEGF and with
poor prognosis. They described that HIF-1 and HIF-2 ex-
pression was observed in both cytoplasmic and nuclear por-
tions, and regarded both expression patterns as positivity for
HIF-1 and HIF-2 proteins (13). However, the impact of
HIF-1 protein on tumor growth kinetics of NSCLC is not
still defined.
In the present study we studied the differential immuno-
histochemical expression of HIF-1 protein according to com-
mon histologic types of NSCLCs when only nuclear HIF-1
staining was adopted as positivity. In addition, HIF-1 expres-
sion was also analysed in comparison with microvessel density
(MVD), VEGF expression, proliferating cell nuclear antigen
(PCNA) index, and clinical prognostic parameters in NSCLCs.
MATERIALS AND METHODS
Eighty-four NSCLC samples used in this study were obtai-
ned from patients who underwent lobectomy or pneumonec-
tomy for operable lung cancers. They all were diagnosed at
the Department of Pathology, Pusan National University
Hospital between 1998 and 2000. The tumors were composed
of 45 cases of squamous cell carcinoma (SCC) and 39 of ade-
nocarcinoma (AC).
The latter was composed of acinar or papillary ACs of peri-
pheral type. Seven cases of them showed focal bronchioloalve-
olar carcinoma (BAC) pattern. As for ACs with BAC pattern,
separate subtyping was not performed because they were gen-
erally known to show similar biologic behavior with usual ACs.
Resected lung tissues were fixed immediately in 10% buf-
fered formalin (pH 7.0) and embedded in paraffin, and 4  m-
thick serial sections were prepared. For histopathological diag-
nosis, one of these sections was stained with hematoxylin-eosin.
The others were used for immunohistochemistry. The patho-
logical diagnosis was based on light microscopic examination,
according to the WHO classification (14).
Immunohistochemical staining
Sections from paraffin-embedded blocks were transferred
to poly-L-lysine coated glass slides and air-dried overnight at
37℃. They were dewaxed in xylene (three changes), rehydrat-
ed in a graded series of decreasing ethanol concentrations, and
then rinsed in Tris-buffered saline (50 mM Tris/HCl, pH 7.4,
containing 100 mM sodium chloride). For the blockage of
endogenous peroxidase activity, sections were immersed for
20 min in methanol containing 0.3% hydrogen peroxide.
Table 1 presents the summary of immunohistochemical panel
used in this study. For the detection of HIF-1 , tissue sections
were immersed in 10 mmol/L citrate buffer (pH 6.0), and sub-
jected to microwave irradiation for 5 min×3. After antigen
retrieval, a cooling-off period of 30 min was followed, and
HIF-1 antibody was incubated with the tissue sections one
hr at 20℃ in moisture chamber. Thereafter, the catalysed
signal amplification system (DAKO Co., Carpinteria, CA,
U.S.A.) was used according to the manufacturer’s instructions.
All other antibodies to CD34, VEGF and PCNA were used
without antigen retrieval treatment. They were incubated with
the tissue sections overnight at 4℃, and then immunohis-
tochemical procedures were performed by Histostain Plus kit
(Zymed Laboratories Inc., South San Francisco, CA, U.S.A.)
using the standard streptavidin-biotin complex method. The
reaction products were visualized by exposing sections to 3,3-
diaminobenzidine for HIF-1 , and to 3-amino-9-ethylcarbazole
for the others. Nuclei were lightly counterstained for about
20 sec with Meyer’s hematoxylin. Sections were then mount-
ed in diluted malinol after the application of Universal Mount
(DAKO, Carpinteria, CA, U.S.A.). Tissue samples incubat-
ed with non-immune serum served as negative controls. Breast
cancer tissue sections with strong nuclear HIF-1 expression
were used as positive controls.
Immunohistochemical interpretation
All immunohistochemical evaluation was performed by two
independent observers. Interobserver variability was minimal
(p<0.05 by  2 test). HIF-1 staining was regarded as positiv-
ity if the tumor cells of more than 1% within tumor tissue
showed completely darkly stained nuclei. Cytoplasmic stain-
ing, observed occasionally, was ignored because active HIF-
1 is located only in the nucleus (15). Angiogenic activity was
assessed by estimating CD34-positive microvessels in the sur-
rounding stroma of invasive tumor nests as described in the
literature (16). In short, in four adjacent fields of vision in the
most vascularized area, microvessels were counted at ×200
magnification using an Olympus microscope (BX 50, Olym-
pus Optical Co., Japan), and then MVD was expressed as the
mean value of microvessels/mm2 for each case. For PCNA
evaluation, we examined at least 500 tumor cells, to determine
whether the nuclei of the cells were positive for the PCNA stain-
ing at high power (×400) after screening for areas of highest
intense staining at low power (×100). We did not divide the
MAb, monoclonal antibody; poly, polyclonal antibody; MW, microwaving
with 10 mM/L citrate buffer, pH 6.0 (3×5 min.); ND, not done; *, Novus
Biological Inc., Littleton, CO, USA; 
� , NeoMarkers, Union City, CA, USA; 
� ,
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA; 
�, Sigma Chemical
Co., St. Louis, Mo, USA.
Antigen Source Antigen
retrieval
Dilution Antibody clone
HIF-1 Mouse Mab (H1a67) 1:1,000 MW Novus*
CD34 Mouse Mab (QBEnd/10) 1: 50 ND NeoMarkers
�
VEGF Goat poly (A20) 1: 50 ND Santa Cruz
�
PCNA Mouse Mab (PC10) 1: 1,500 ND Sigma
�
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PCNA-expression level. Instead we used the percentage of
PCNA-positive cells (PCNA index) for all analyses. For eval-
uation of VEGF expression a score corresponding to the sum
of both (a) staining intensity (0, negative; 1, weak; 2, inter-
mediate; 3, strong) and (b) percentage of positive cells (0, 0%
positive cells; 1, <25% positive cells; 2, 26-50% positive cells;
3, >50% positive cells) was determined. Their sum reached a
maximum score of 6. A score greater than 2 was regarded as
positive (17).
Statistical analysis
To evaluate whether the elevated level of HIF-1 correlated
with histologic types, VEGF expression, lymph node status,
and clinical stages, we performed  2 test for trend. Associa-
tions between HIF-1 expression and PCNA index and MVD
were analysed with Student t-test. Within the cases of HIF-
1 positive NSCLC, we also evaluated the relationship between
histologic types and VEGF expression by  2 test and between
histologic types and PCNA index and MVD by Mann Whit-
ney U test. Finally with relation to histologic parameters in-
cluding HIF-1 expression, histologic type, VEGF expression,
MVD, and PCNA index, each survival curve was analyzed
using the Kaplan-Meier methodology. Then the log-rank test
was used to determine statistical differences between life tables.
All analyses were performed with the SPSS statistical package
on a personal computer, Release 10.0.1 (SPSS Inc., Chicago,
IL). p values less than 0.05 were regarded as statistically sig-
nificant. All statistical tests were two-sided.
RESULTS
Relationship between HIF-1 expression and clinico-
pathologic parameters in SCCs and ACs of lung
Immunoreactivity of HIF-1 was found in 38 of 84 cases of
pulmonary SCCs and ACs (45.2% in positivity). For histolog-
ic type, SCCs showed HIF-1 positivity in 30 out of 45 cases
(66.7%), whereas ACs showed the positivity in 8 out of 39
cases (20.5%). HIF-1 expression was significantly different
between the two histologic types (p<0.001; Table 2). Among
SCC, squamous cell carcinoma; AC, adenocarcinoma; LNM, lymph node
metastasis; MVD, microvessel density. * and 
� , expressed as mean±SD.
Parameters
Total
(No. of cases)
HIF-1
Negative Positive
p value
Histologic SCC 45 15 30 <0.001
types AC 39 31 8
LNM Yes 34 20 14 0.753
No 47 26 21
Stage I 39 20 19 0.570
II 14 8 6
III 28 18 10
VEGF Negative 27 18 9 0.131
Positive 57 28 29
MVD (/mm
2)* 84 17.8±10.1 20.5± 9.7 0.215
PCNA (%)
� 84 46.2±22.0 54.9±22.3 0.077
Table 2. Relationship between HIF-1 expression and clinico-
pathologic parameters in squamous cell carcinomas and ade-
nocarcinomas of the lung
Fig. 1. Immunostaining for HIF-1 protein. (A) Squamous cell carcinoma shows dark brown nuclear staining, predominantly around necrot-
ic area of the tumor (×40). (B) Moderately differentiated adenocarcinoma reveals positive nuclear reaction in a randomly scattered fash-
ion (×100). N, necrotic area.
A B
N
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39 SCC cases showing HIF-1 positivity, 22 cases exhibited
the positive reaction predominantly around necrotic zones of
tumor nests (Fig. 1A), and the others revealed the positivity in
both around necrosis and non-necrotic area. In comparison with
SCCs, five of the positive eight cases of ACs revealed the pos-
itive reaction only in non-necrotic areas (Fig. 1B), and three of
them showed the combined positive reaction in both non-
necrotic areas and around necrotic zones of tumor nests
(Table 3). In ACs the positive reaction displayed the tenden-
cy to occur in histologically poorly differentiated tumor por-
tions. In both histologic types, HIF-1 positive tumor cells
was focally scattered in small clusters. In contrast to SCCs,
ACs more frequently showed cytoplasmic immunoreactivity
which was regarded as negative reaction. Some non-neoplastic
respiratory epithelial tissues neighboring to carcinomas also
displayed focal nuclear positive reaction. 
With the whole cases of this study, HIF-1 expression was
not correlated with lymph node status, tumor stage, VEGF ex-
pression, MVD, or PCNA index (p>0.05, respectively; Table 2).
VEGF expression, MVD, and PCNA index according
to SCCs and ACs of lung
Immunoreactivity for VEGF showed no association be-
tween the two histologic types (68.9% in SCCs vs 66.7% in
ACs, p=0.828; Table 4). In the positive cases the reaction was
noted in the cytoplasm of tumor cells over the large areas of
tumors (Fig. 2). In addition to tumor cells, stromal cells also
displayed positive reaction. CD34 immunoreactivity for MVD
was heterogeneous, with no difference between the central
Fig. 2. Immunostaining for VEGF. (A) Squamous cell carcinoma shows reddish brown cytoplasmic staining in a diffuse fashion (×200). (B)
Adenocarcinoma reveals the positive cytoplasmic reaction in a rather focal pattern (×200).
A B
SCC, squamous cell carcinoma; AC, adenocarcinoma. *, positive nucle-
ar staining presenting in both around necrosis and non-necrotic area.
Histologic types
Distribution of HIF-1 staining
Only around
necrosis
Only non-necrotic
area
Combined* 
SCC 22 0 8
AC 0 5 3
Table 3. Distribution of HIF-1 staining in squamous cell carci-
nomas and adenocarcinomas of the lung
SCC, squamous cell carcinoma; AC, adenocarcinoma; MVD, microves-
sel density.
Histologic
types
VEGF (No. of cases)
Negative Positive
PCNA (%) MVD (/mm
2)
SCC 14 31 21.7±9.4 55.6±21.9
AC 13 26 16.0±9.8 43.9±21.6
p value 0.828 0.009 0.016
Table 4. VEGF expression, MVD, and PCNA index in squamous
cell carcinomas and adenocarcinomas of the lung
SCC, squamous cell carcinoma; AC, adenocarcinoma; MVD, microves-
sel density.
Histologic types VEGF (Positivity, %) PCNA (%) MVD (/mm
2)
SCC 24/30 (80.0) 21.5±8.5 54.2±20.7
AC 5/8 (62.5) 12.7±7.4 42.2±24.4
p value                             0.363 0.023 0.227
Table 5. VEGF expression, microvessel density, and PCNA index
according to HIF-1 positive squamous cell carcinomas and
adenocarcinomas of the lung200 C.H. Lee, M.K. Lee, C.D. Kang, et al.
and marginal tumor areas. MVD revealed a significant dif-
ference beween the two histologic types (21.7±9.4 microves-
sels/mm2 in SCCs vs 16.0±9.8 microvessels/mm2 in ACs,
p=0.009; Fig. 3; Table 4). The PCNA index also showed a
significant difference between the two histologic types (55.6
±21.9% in SCCs vs 43.9±21.6% in ACs, p=0.016; Fig.
4; Table 4).
VEGF expression, MVD, and PCNA index according
to HIF-1 positive SCCs and ACs
VEGF expression was present in 24 of 30 cases (80.0%) of
HIF-1 positive SCCs, and in 5 of 8 cases (62.5%) of HIF-1
positive ACs. Compared with HIF-1 positive AC, HIF-1
positive SCCs showed the tendency of higher VEGF expres-
sion, but there was no association between histologic types
Fig. 3. Immunostaining for CD34. (A) Squamous cell carcinoma shows increased CD34-positive microvessels in the interfaces between
carcinoma nests and stoma (×100). (B) Adenocarcinoma also reveals increased CD34-positive microvessels around the tumor (×100).
A B
Fig. 4. Immunostaining for PCNA. (A) Squamous cell carcinoma shows diffuse strong positivity in the nuclei of the tumor cells (×100). (B)
Adenocarcinoma  reveals the positive nuclear reaction in a rather focal pattern (×100).
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(p=0.363; Table 5). MVD was significantly higher in HIF-1
positive SCCs than in HIF-1 positive ACs (p=0.023; Table
5). The PCNA index turned out to exhibit no difference be-
tween the two histologic types showing HIF-1 positivity
(p=0.227; Table 5).
Survival analysis
During the course of this study (maximal follow-up, 132
months; minimal follow-up, 1 month; median follow-up, 23
months), 9 cases were lost to follow-up. In this analysis all pa-
tients died of the disease, and data on postoperative treatment
were not available. As for MVD and PCNA index, we used
the median values (17.8 microvessels/mm2and 43.0%, respec-
tively) as cut-off points in the univariate analysis of survival.
Firstly, with regard to HIF-1 expression, 14 of the positive
34 patients were censored and 20 died (mean and median
survival times, 47.3 and 29.0 months, respectively). Nine of
the negative 41 patients were censored and 32 died (mean and
median survival times, 36.9 and 24.0 months, respectively).
The overall survival was not associated with HIF-1 expres-
sion (p=0.442 by log-rank test). It also had no relation with
histologic types, VEGF expression, MVD, or PCNA index
(p=0.672, p=0.277, p=0.890, and p=0.573 by log-rank test,
respectively).
DISCUSSION
HIF-1 protein is known to activate the transcription of
genes encoding transferrin, VEGF, endothelin-1, and inducible
nitric oxide synthetase, which are implicated in vasodilation,
neovascularization, and tumor metastasis, and plays an essen-
tial role in oxygen homeostasis (2, 18, 19). In the present study,
we investigated the differential expression of HIF-1 protein
among common histologic types of NSCLC. In the cases of
SCC, HIF-1 positive cells were predominantly located around
tumor necrosis. The predominant perinecrotic expression of
HIF-1 protein indicates that the hypoxic tumor microen-
vironment may directly contribute for induction of HIF-1
activity in these cancers. Nevertheless, some positively stain-
ing cells were also present in non-necrotic tumor nests. In
the lower parts of columnar or squamous metaplastic epithe-
lium neighboring to the tumor, the focal expression of HIF-
1 protein was also observed, which would be consistent with
the presence of low pH and hypoxia. In the cases of AC, how-
ever, it was interesting that the increased level of HIF-1 pro-
tein was noted more frequently in poorly differentiated areas
than in necrotic areas. This finding may reflect the existence
of alternative regulatory modes of HIF-1 expression. Altered
patterns of gene expression in cancer could arise both from
genetic alterations in the tumor cells and from stimulation
by an abnormal microenvironment within the tumor. As a
matter of fact, a growing line of evidence indicates that both
oncogene activation and tumor suppressor gene inactivation
are also associated with increased HIF-1 expression (20-22).
In other words the persistent HIF-1 expression in poorly
differentiated ACs may show the emergence of an aggressive
phenotype with high oxygen consumption as a result of the
transformation itself and not of the hypoxic environment. HIF-
1 expression has been shown to be enhanced by v-src (20)
and in response to several growth factors, including insulin-
like growth factors (IGFs) 1 and 2, basic fibroblast growth
factor, and epidermal growth factor (23). Activation of the
phosphatidylinositol 3-kinase/AKT/FRAP pathway, which
mediates signals from a broad range of growth factors, has
likewise been demonstrated to increase HIF-1 expression
(24). Though the precise mechanism of these interfaces with
the hypoxia-sensitive pathway is still not clear, those findings
suggest a more general influence of growth-promoting stim-
uli on HIF-1 activity. Thus, our results indicate that there
may exist a different molecular event in tumor progression
between SCCs and ACs.
Although the HIF-1 protein is commonly up-regulated in
a variety of cancers, the positive staining is known not to be
universal. At present there is no certain explanation for this
discrepancy. However, the prolonged fixation on pellets of
hypoxic cells is known to substantially compromise antigen
detection, so that failure to stain some tumors might be arti-
ficial. In the survey of tissue culture cells by immunoblot anal-
ysis, Wiesener et al. (4) found that under maximal hypoxic
stimulation, all cells had detectable levels of at least one HIF
subunit, albeit the levels were quite variable. On the basis of
the above finding, it is possible that relatively low levels of
induced expression were still below the detection threshold
in this immunohistochemical analysis, or that some tumors
were relatively well oxygenated so that the HIF-1 protein
was not induced in the sections examined. Some tumors that
were negative for the HIF-1 protein in our cases also may
express the HIF-1 protein at levels below the limits of
detection by the current immunohistochemical methodolo-
gy. Otherwise other transcription factors that may have simi-
lar biological properties to HIF-1 , such as HIF-2 or HIF-
3 , may also mediate hypoxic adaptation in tumors (25, 26).
Zhong et al. (12) found that the HIF-1 expression was
noted in premalignant lesions such as colonic adenoma, breast
ductal carcinoma in situ, and prostatic intraepithelial neopla-
sia, whereas every benign tumor was negative for the HIF-1
expression. They suggested that HIF-1 expression can occur
very early in carcinogenesis. In our study, premalignant lesions
were not included, but exceptionally a few of non-neoplastic
epithelial cells adjacent to cancer showed the immunoreactiv-
ity for the HIF-1 protein. Zhong et al. (12) also found a sig-
nificant association of HIF-1 expression with Ki-67 prolif-
eration index. But we could not confirm a significant associ-
ation of HIF-1 expression with the PCNA index in our cases
of SCC and AC, although the use of a different proliferation
marker might be related with this discrepancy. We also found202 C.H. Lee, M.K. Lee, C.D. Kang, et al.
that the PCNA index in overall SCCs was significantly high-
er than that in overall ACs, but within the category of HIF-
1 positive carcinomas the index did not show a significant
difference between the two histologic types. Maybe this incon-
sistency stems from the hypothesis that pulmonary SCCs form
a heterogeneous group of tumors with different biological
properties and clinical behaviors (27). Feldser et al. (23) report-
ed that the treatment of cultured prostatic carcinoma cells
with insulin, IGF-1, or IGF-2 induced the expression of HIF-
1 protein, which was in turn required for expression of IGF-
2 mRNA, suggesting the involvement of HIF-1 protein in
an autocrine growth factor loop. Thus, the HIF-1 expression
may be associated with growth factors, which endowed tumors
with a higher PCNA index.
Since HIF-1 stabilization up-regulates the expression of
angiogenic and glycolytic pathways to restore oxygen homeo-
stasis, the HIF-1 protein may have an important role for
the survival and growth of cancer. We examined the expres-
sion of the most representative angiogenic factor VEGF and
MVD in SCCs and ACs. The MVD of SCCs was significant-
ly higher than that of ACs, whereas the VEGF expression of
SCCs showed no significant difference from that of ACs. Even
within the category of HIF-1 positive carcinomas, this ten-
dency was also observed between SCCs and ACs. Thus, the
MVD that we assessed by CD34 immunoreactivity was relat-
ed to a specific histologic type of HIF-1 positive carcino-
mas. These findings somewhat reflect the impact of HIF-1
protein on the angiogenic process of common NSCLCs, espe-
cially SCCs. Otherwise the tendency of increasing MVD in
SCCs could be associated with tumor necrosis, which was
more frequently found in these types of cancer. On the con-
trary, Tsoli et al. (28), who used CD31 as the endothelial cell
marker, reported no relationship between histologic types
and MVD. This discrepancy is most likely associated with
differences in the evaluation of the results, the use of differ-
ent endothelial cell marker, and tumor heterogeneity. As
concerned with VEGF, the lack of direct correlation between
HIF-1 and VEGF expression might suggest that although
hypoxia triggers the expression of VEGF through HIF-1
stabilization, the process of angiogenesis in pulmonary SCCs
and ACs is also subject to other modulators such as platelet-
derived endothelial cell growth factor, bcl-2, c-erbB-2, and
MUC1 glycoprotein (29-31). But our result was in contrast
with those of Giatromanolaki et al. (13), who reported the
strong association between HIF-1 expression and VEGF
expression. This discordance may be related with the differ-
ent interpretation methods in immunohistochemical stain-
ing. They regarded both nuclear and cytoplasmic staining
as HIF-1 positivity. As far as we know, although the HIF-
1 protein is synthesized in the cytoplasm and also degrad-
ed in the cytoplasm, it would be assumed that only nuclear
HIF-1 is the active form (15). However, we consider that
the relationship between HIF-1 and angiogenic factors needs
to be clarified, with the development of more strict criteria
for immunohistochemical interpretation.
Finally, we observed no association between the overall
survival of the patients and HIF-1 expression (p=0.442).
This result was rather different from that of Giatromanolaki
et al. (13) who reported that HIF-1 positive group was
marginally related (p=0.08) to poor outcome. In addition, we
also found no association between the overall survival and
histologic parameters including histologic types, VEGF ex-
pression, MVD, and PCNA index. As concerned with MVD
and VEGF expression, some workers suggested that the two
parameters were not correlated with the survival (28, 32).
However, other researchers reported that both MVD and
VEGF expression were linked to poor survival (29, 33, 34).
These discrepant observations may be explained by the dif-
ferent methodologies applied, the different approaches to the
estimated results, and the cut-off levels used (28).
In conclusion, we suggest that the HIF-1 expression, which
can occur with hypoxic tumor environment in SCCs or with
histological dedifferentiation in ACs, may play a differential
role according to the histologic types of common NSCLCs.
Thus, it seems that the process of HIF-1 expression is con-
trolled by different mechanisms between the two histologic
types.
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